



Huber, J., Hüsler, J., Dieppe, P., Günther, K. P., Dreinhöfer, K., & Judge, A. (2016). A new responder criterion (relative effect per patient (REPP) > 0.2) externally validated in a large total hip replacement multicenter cohort (EUROHIP). *Osteoarthritis and Cartilage*, 24(3), 480-483. <https://doi.org/10.1016/j.joca.2015.10.012>

Publisher's PDF, also known as Version of record

License (if available):
CC BY-NC-ND

Link to published version (if available):
[10.1016/j.joca.2015.10.012](https://doi.org/10.1016/j.joca.2015.10.012)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via Elsevier at [https://www.oarsijournal.com/article/S1063-4584\(15\)01365-5/fulltext](https://www.oarsijournal.com/article/S1063-4584(15)01365-5/fulltext) . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Osteoarthritis and Cartilage



Brief report

A new responder criterion (relative effect per patient (REPP) > 0.2) externally validated in a large total hip replacement multicenter cohort (EUROHIP)



J. Huber [†]*, J. Hüsler [‡], P. Dieppe [§], K.P. Günther ^{||}, K. Dreinhöfer [¶]#, A. Judge ^{††}

[†] Department of Orthopaedics, Stadtspital Triemli, Birmensdorferstr. 497, CH-8063 Zurich, Switzerland

[‡] Institute for Mathematical Statistics, University of Bern, Sidlerstr. 5, CH-3012 Bern, Switzerland

[§] Peninsula College of Medicine and Dentistry, C420 Portland Square, University of Plymouth Campus, Drake Circus, Plymouth PL4 8 AA, UK

^{||} Department of Orthopaedics, Gustav Carus University of Dresden, Fetscherstr. 76, D-01307 Dresden, Germany

[¶] Centre of Musculoskeletal Surgery, Charité, University of Berlin, Charitéplatz 1, D-10117 Berlin, Germany

[#] Department of Orthopaedics, Traumatology and Sports Medicine, Medical Park Berlin Humboldtmühle, An der Mühle 2-9, D-13507 Berlin, Germany

^{††} Botnar Research Centre, Institute of Musculoskeletal Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Headington, OX3 7LD, UK

ARTICLE INFO

Article history:

Received 15 April 2015

Accepted 21 October 2015

Keywords:

Responder
OMERACT-OARSI
REPP
THR
Outcome
EUROHIP

SUMMARY

Objective: To validate a new method to identify responders (relative effect per patient (REPP) > 0.2) using the OMERACT-OARSI criteria as gold standard in a large multicentre sample.

Method: The REPP [(score before – after treatment)/score before treatment] was calculated for 845 patients of a large multicenter European cohort study for THR. The patients with a REPP > 0.2 were defined as responders. The responder rate was compared to the gold standard (OMERACT-OARSI criteria) using receiver operator characteristic (ROC) curve analysis for sensitivity, specificity and percentage of appropriately classified patients.

Results: With the criterion REPP > 0.2 85.4% of the patients were classified as responders, applying the OARSI-OMERACT criteria 85.7%. The new method had 98.8% sensitivity, 94.2% specificity and 98.1% of the patients were correctly classified compared to the gold standard.

Conclusion: The external validation showed a high sensitivity and also specificity of a new criterion to identify a responder compared to the gold standard method. It is simple and has no uncertainties due to a single classification criterion.

© 2015 The Authors. Published by Elsevier Ltd and Osteoarthritis Research Society International. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Total hip replacement (THR) is one of the most successful treatment procedures for patients with hip osteoarthritis; THR alleviates the symptoms (e.g., pain and stiffness) and degree of disability^{1–4}. The success of THR can be measured as responder rate defined by Outcome Measures in Rheumatoid Arthritis Clinical Trials/Osteoarthritis Research Society International (OMERACT-OARSI) with patient reported outcome measurement tools (PROM's)^{5–11}. The responder rate for a surgical treatment (e.g., THR)

contains valuable information and is easy to understand either for patients and general practitioners, surgeons and medical care providers^{12–14}. For example in the multicenter EUROHIP study the responder rate for THR was 85.4%, meaning that 6 out of 7 patients had a clinical improvement above the level of a minimally clinically important difference and one of 7 patients does not profit from THR (being a “non-responder”)¹². This information may be helpful either for decision making for the patients and for process amelioration for surgeons analyzing possible factors to become a responder or possible factors to become a “non-responder”.

But the method to calculate the responder rate is complex because one main criterion or two out of three subcriteria regarding pain or function needed to be fulfilled⁵. An easier method simple to calculate would be helpful to overcome this limitation. In the validation study of the relative effect per patient (REPP) [Fig. 1]

* Address correspondence and reprint requests to: J. Huber, Department of Orthopaedics, Stadtspital Triemli, Birmensdorferstr. 497, Postfach, CH 8063 Zurich, Switzerland. Tel: 41-44-466-19-40; Fax: 41-44-466-32-43.

E-mail address: joerg.huber2@triemli.zuerich.ch (J. Huber).

$$\text{REPP} = \frac{(\text{pre-treatment score}) - (\text{post-treatment score})}{(\text{pre-treatment score})}$$

Example 1: pre-treatment score 48, post-treatment score 2;

REPP = $48 - 2 / 48 = 46 / 48 = 0.96 = \text{responder}$

Example 2: pre-treatment score 25, post-treatment score 16;

REPP = $25 - 16 / 25 = 9 / 25 = 0.36 = \text{responder}$

Example 3: pre-treatment score 13, post-treatment score 35;

REPP = $13 - 35 / 13 = -22 / 13 = -0.63 = \text{non-responder}$

Fig. 1. REPP formula and calculating REPP scores: three examples.

the threshold was defined with 0.2, representing a change equal or larger than the minimal clinically important difference (MCID)¹⁵. Incidentally a high agreement was found between the patients with a REPP > 0.2 (91%) and the responder rate using the set of OMERACT-OARSI criteria (92%)¹⁵.

The aim of this study was to validate this finding externally in a highly generalizable sample of patients undergoing THR for primary OA in 12 European nations and to determine whether it identifies the same patients as responders using the OMERACT-OARSI method as the gold standard.

Method

We included patients who were enrolled in the EUROHIP study and had complete PROMs from the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) follow-ups pre-THR and one year postoperatively for the patients with unilateral THR^{4,12}. The EUROHIP study included 1327 patients who underwent primary THR at 20 European orthopedic centers in 12 nations. The study began by collecting data in January 2004 and concluded in December 2006. The inclusion criteria were having a diagnosis of hip OA, undergoing primary THR, and providing signed informed consent. The exclusion criteria were severe mental illness or dementia and patients who were unwilling/unable to participate. Each center was responsible for obtaining local ethical approval. The study protocol and data collection forms were designed in Bristol, UK and Ulm, Germany by the study principle investigators (Paul Dieppe, Klaus-Peter Günther and Karsten Dreinhöfer). The patient questionnaire was reviewed for acceptability in Bristol and modified accordingly before it was sent to Ulm for translation and distribution. Questionnaires were sent to each center for translation and were returned for editing before being printed and distributed with a set of instructions.

The WOMAC score was calculated including all 24 questions of three dimensions pain, stiffness and physical function on a scale 0 indicating no symptoms and 100 extreme symptoms.

Outcome

We defined the patient outcome using the responder rate calculated with the REPP score (REPP > 0.2) as new criterion and compared it to the rate using the OMERACT-OARSI criteria as gold standard.

REPP score and responder criterion

The REPP (pre treatment (tt) score – post tt score)/pre tt score) was calculated for each patient with the WOMAC score [Fig. 1]. Every patient with a REPP > 0.2 was defined as responder¹⁵.

OMERACT-OARSI responder criteria

The OMERACT-OARSI responder criteria (Pham *et al.*) indicate a substantial improvement in pain or function of ≥50% and an

absolute change of ≥20. If the patient does not fulfill these criteria, improvement in ≥2 of the three following criteria is necessary: ≥20% improvement in pain and an absolute change of ≥10, ≥20% improvement in function and an absolute change of ≥10, ≥20% improvement in the patient's global assessment, and an absolute change of ≥10⁵.

Statistical analysis

Descriptive statistics were used to determine the score variability before and after THR, as well as the number of responders. Cross tabulation of both methods was conducted to assess the percentage of patients who were appropriately classified. Receiver operator characteristic (ROC) curve analysis was used to assess the sensitivity, specificity, and percentage of patients who were appropriately classified compared to the newly proposed method, using the OARSI as the gold standard. Stata 13.1 software (Stata Corp., College Station, TX, USA) was used for all statistical analyses.

Results

All patients with complete outcome data from the preoperative and 12-month postoperative assessments ($n = 845$, comprising 63.7% of all included patients) were included. The average patient age was 65.7 years (range, 26–92 years).

The median WOMAC score of the patients before and after THR decreased from 58.3 to 15.6 ($P < 0.001$). The REPP-scores ranged from 1 to –1.5, peaking at approximately 1 and slowly decreasing to zero; there were few results near or below zero, as well as an outlier. For the EUROHIP cohort, the relative proportions of responders were 85.4% and 14.6% non-responders (12.7% unchanged, and 1.9% worse). Using the OARSI-OMERACT criteria, we identified 85.7% of the patients as responders.

Both methods classified nearly the same patients as responders with 98.8% sensitivity, 94.2% specificity and 98.1% correctly classified, demonstrating good validation of the new REPP method to calculate the responders [Fig. 2].

Discussion

Main findings

The criterion REPP > 0.2 to define a responder correlates with high sensitivity and also high specificity with the existing set of OARSI-OMERACT criteria. The responder rate can be calculated simple and easier with REPP method.




Fig. 2. Venn-diagram to show overlap between REPP score and OARSI-OMERACT responder criteria.

Strengths/limitations

The strength of this study is the large number of participating patients in 12 nations with PROM's in 10 different languages at 20 centers allowing a reliable external validation of this new method.

Study limitations were the selection bias of patients and treatment.

The included patients (unilateral osteoarthritis of the hip, undergoing THR) were similar to those in the validation study.

A basic bias of the EUROHIP study group was that all participating surgeons and centers had a special interest in THR and in clinical science; therefore, the analyzed cohort may represent a positive patient selection and the responder rate may be higher than in general practice.

Author contributions

All authors have contributed to each of the three activities:

- 1) The concept of the REPP and the application of the new responder criterion the EUROHIP study cohort and the data acquisition of the cohort especially for the clinical part measuring the outcome
- 2) Drafting the article or revising it critically for important intellectual content
- 3) Approval of the final version, and will take public responsibility for the content of the paper.

Role of the funding source

None.

Competing interests

None.

Acknowledgements

We wanted to thank all participants and all participating clinics of the EUROHIP study group: M. Krismer, B. Stoeckl, University Clinic Orthopaedic Surgery, Innsbruck, Austria; K. Knahr, O. Pinggera, Orthopedic Hospital Wien-Speising, Austria; P. Ylinen, Orton Orthopaedic Hospital, Helsinki, Finland; M. Hamadouche, Groupe Hospitalier Cochin, Paris, France; Ch. Delaunay, Clinique De L'Yette, Longjumeau, France; Ph. Chiron, Centre Hospitalier Ranguell, Toulouse, France; W. Puhl, K. Dreinhöfer, M. Floeren, S. Baumann and D. Groeber-Graetz University of Ulm (RKU), Ulm, Germany; KP Günther, St. Fickert, Carl Gustav Carus University, Dresden, Germany; J. Löhr, A. Katzer and D. Klüber ENDO Clinic, Hamburg, Germany; V. Ewerbeck, P. Aldinger, D. Parsch, University of Heidelberg, Heidelberg, Germany; W. Neumann, I. Meinecke and Th. Bittner, Otto von Guericke University, Magdeburg, Germany; W. von Eiff and C. Middendorf, Center for Hospital Management (CKM), Munster, Germany; HP Scharf, P. Schraeder and S. Schmitt, University Clinic Mannheim, Mannheim, Germany; D. Rowley Ninewells Hospital and Medical School, Dundee, UK; I. Learmonth, Avon Orthopaedic Centre, Bristol, UK; P. Dieppe, V. Cavendish and S. Williams, HSRC University of Bristol, Bristol, UK; P. Kellermann and I. Fister, University of Szeged, Szeged, Hungary; Th. Ingvarsson, Akureyri University Hospital, Iceland; P. Gallinaro and A. Masse, Università degli Studi di Torino, Torino, Italy; A. Gorecki and M. Amboziak, Medical University of Warsaw, Warsaw, Poland; E. Garcia Cimbrello, Hospital La Paz, Madrid, Spain; A. Nilsdotter and U. Bengtsson, Helsingborg Hospital, Skane, Sweden; Chr. Hellerfelt and Chr. Olson, Lasarett Karlshamn, Sweden; J. Huber and I. Broger, Kantonsspital, Aarau, Switzerland; R. Theiler, K. Uehlinger and A. Hett Stadtsptial Triemli,

Zurich, Switzerland; Til Stuermer, Harvard Medical School, Boston, USA.

References

1. Learmonth ID, Young C, Rorabeck C. The operation of the century: total hip replacement. *Lancet* 2007;370:1508–19.
2. Shan L, Shan B, Graham D, Saxena A. Total hip replacement: a systematic review and meta-analysis on mid-term quality of life. *Osteoarthritis Cartilage* 2014;22:389–406.
3. Judge A, Arden NK, Batra RN, Thomas G, Beard D, Javaid MK, et al. The association of patient characteristics and surgical variables on symptoms of pain and function over 5 years following primary hip-replacement surgery: a prospective cohort study. *BMJ Open* 2013;3.
4. Judge A, Cooper C, Williams S, Dreinhoefer K, Dieppe P. Patient-reported outcomes one year after primary hip replacement in a European collaborative cohort. *Arthritis Care Res* 2010;62:480–8.
5. Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. *Osteoarthritis Cartilage* 2004;12:389–99.
6. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. *J Rheumatol* 1988;15:1833–40.
7. Nilsdotter AK, Lohmander LS, Klässbo M, Roos EM. Hip disability and osteoarthritis outcome score (HOOS) – validity and responsiveness in total hip replacement. *BMC Musculoskeletal Disord* 2003;4:10.
8. Huber J, Zuberbühler U, Dabis E, Zumstein M, Rüfelin G. A simple orthopaedic patient questionnaire to measure symptoms and disabilities – validation experience. *Z Orthop Unf* 2008;146:793–8.
9. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertain the minimal clinically important difference (MCID). *Control Clin Trials* 1989;10:407–15.
10. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. *Arthritis Care Res* 2001;45:384–91.
11. Quintana J, Escobar A, Bilbao A, Arostegui I, Lafuente I, Vidaurreta I. Responsiveness and clinically important differences for the WOMAC and SF-36 after hip joint replacement. *Osteoarthritis Cartilage* 2005;13:1076–83.
12. Judge A, Cooper C, Arden NK, Williams S, Hobbs N, Dixon D, et al. Pre-operative expectation predicts 12-month post-operative outcome among patients undergoing primary total hip replacement in European orthopaedic centres. *Osteoarthritis Cartilage* 2011;19:659–67.
13. Escobar A, Gonzalez M, Quintana JM, Vrotsou K, Bilbao A, Herrera-Espineira C, et al. Patient acceptable symptom state and OMERACT-OARSI set of responder criteria in joint replacement. Identification of cut-off values. *Osteoarthritis Cartilage* 2012;20:87–92.

14. Schäfer T, Krummenauer F, Mettelsiefen J, Kirschner S, Günther KP. Social, educational, and occupational predictors of total hip replacement outcome. *Osteoarthritis Cartilage* 2010;18:1036–42.
15. Huber J, Dabis E, Zumstein MD, Huesler J. Relative effect per patient (REPP) — outcome groups for total hip replacement and total knee replacement. *Z Orthop Unf* 2013;151:239–43.